Wednesday, Oct 27, 1999

Genentech and Chairman/CEO Levinson to Receive National Breast Cancer Coalition's Corporate Leadership Award

South San Francisco, Calif. -- October 27, 1999 --

Genentech, Inc. (NYSE: DNA) today announced the company and its chairman and chief executive officer Arthur D. Levinson, Ph.D. will be honored with the 1999 Corporate Leadership Award from the National Breast Cancer Coalition (NBCC). Levinson and Genentech are being recognized for the company's groundbreaking partnership with breast cancer advocates in the research process for Herceptin® (Trastuzumab) monoclonal antibody, indicated for the treatment of certain patients with metastatic breast cancer. NBCC is a grassroots advocacy organization dedicated to eradicating breast cancer through action and advocacy.

"The partnership with Genentech around the Herceptin clinical trial is a model for future endeavors between advocates and the scientific, medical and research communities," said Fran Visco, president, NBCC.

Genentech partnered with NBCC and other breast cancer advocates around the country on designing, conducting and overseeing the Herceptin clinical trial.

"We are proud and grateful for the recognition of our partnership with NBCC," said Levinson. "This was a great example of how industry and advocates can work together to answer clinical questions and get important new drugs to patients expeditiously."

The Corporate Leadership Award will be presented at NBCC's inaugural San Francisco Gala Dinner at the Regency Ballroom on Thursday, October 28.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Twelve of the approved products of biotechnology stem from Genentech science. Genentech markets seven products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #